sulpiride has been researched along with Prostatic Hyperplasia in 11 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Specific effects of ultra-low doses of antibodies to prostate-specific antigen obtained from laboratory rats of late reproductive age with sulpiride model of benign prostatic hyperplasia were compared with the results of clinical application of the preparation." | 9.15 | Modification of sulpiride model of benign prostatic hyperplasia for evaluation of the effectiveness of drug therapy. ( Borovskaja, TG; Chemerova, JA; Fomina, TI; Jurmazov, ZA; Pahomova, AV; Poluektova, ME; Rumpel', OA; Sergeeva, SA; Udut, VV, 2011) |
| "Specific effects of ultra-low doses of antibodies to prostate-specific antigen obtained from laboratory rats of late reproductive age with sulpiride model of benign prostatic hyperplasia were compared with the results of clinical application of the preparation." | 5.15 | Modification of sulpiride model of benign prostatic hyperplasia for evaluation of the effectiveness of drug therapy. ( Borovskaja, TG; Chemerova, JA; Fomina, TI; Jurmazov, ZA; Pahomova, AV; Poluektova, ME; Rumpel', OA; Sergeeva, SA; Udut, VV, 2011) |
| "Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology." | 3.91 | Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia. ( Borovskaya, TG; Buravlev, EV; Chukicheva, IY; Dygai, AM; Fomina, TI; Goldberg, VE; Grigor'eva, VA; Kamalova, SI; Kuchin, AV; Plotnikov, MB; Poluektova, ME; Vychuzhanina, AV, 2019) |
| "Prostatotropic activity of (3,5-dimethyl-4-hydroxy)benzyl thiododecane (T-DD) was evaluated on a model of benign prostatic hyperplasia induced in Wistar rats by chronic (2 months) intraperitoneal administration of sulpiride (40 mg/kg)." | 3.91 | Morphological Assessment of Prostatotropic Activity of (3,5-Dimethyl-4-Hydroxy)Benzyl Thiododecane on a Model of Benign Prostatic Hyperplasia in Rats. ( Nizomov, SA; Prosenko, AE; Semenov, DE; Sorokina, IV; Tolstikova, TG; Zhukova, NA, 2019) |
| "A course of dihydroquercetin (antioxidant) injections to 5-month-old Wistar rats with sulpiride-induced benign prostatic hyperplasia led to reduction of proliferative activity in the glandular structures and to attenuation of the inflammatory reaction in the tissue." | 3.81 | Dihydroquercetin effects on the morphology and antioxidant/prooxidant balance of the prostate in rats with sulpiride-induced benign hyperplasia. ( Borovskaya, TG; Fomina, TI; Goldberg, VE; Grigor'eva, VA; Kamalova, SI; Krivova, NA; Plotnikov, MB; Poluektova, ME; Shchemerova, YA; Vychuzhanina, AV; Zaeva, OB, 2015) |
| "Afala (ultralow-dose antibodies to prostate-specific antigen) injected for 60 days to rats with hormone-induced prostatitis caused by sulpiride prevented the development of prostatic hyperplasia and reduced the severity of histological changes." | 3.74 | Comparative study of pharmacological activity of afala on the model of hormone-induced prostatitis in rats. ( Borovskaya, TG; Dugina, JL; Epstein, OI; Kheyfets, IA; Savelieva, KV; Sergeeva, SA, 2007) |
| " To enhance PRL release, we induced hyperprolactinemia by administering chronic injections of sulpiride (40 mg." | 3.71 | Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. ( Ahidouch, A; Authie, D; Beauvillain, JC; Carpentier, F; Cousse, H; Croix, D; Dewailly, E; Dupouy, JP; Fournier, S; Le Bourhis, X; Legrand, G; Prevarskaya, N; Raynaud, JP; Slomianny, C; Van Coppenolle, F, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Borovskaya, TG | 4 |
| Kamalova, SI | 2 |
| Grigor'eva, VA | 2 |
| Poluektova, ME | 4 |
| Vychuzhanina, AV | 3 |
| Kuchin, AV | 1 |
| Chukicheva, IY | 1 |
| Buravlev, EV | 1 |
| Fomina, TI | 4 |
| Plotnikov, MB | 2 |
| Goldberg, VE | 2 |
| Dygai, AM | 1 |
| Nizomov, SA | 1 |
| Sorokina, IV | 1 |
| Zhukova, NA | 1 |
| Tolstikova, TG | 1 |
| Semenov, DE | 1 |
| Prosenko, AE | 1 |
| Tsvetkov, IS | 1 |
| Kosyreva, AM | 1 |
| Mkhitarov, VA | 1 |
| Postovalova, EA | 1 |
| Khochanskiy, DN | 1 |
| Makarova, OV | 1 |
| Bredova, OY | 1 |
| Ostrov, VF | 1 |
| Ermolaeva, LA | 1 |
| Pakhomova, AV | 1 |
| Shchemerova, YA | 2 |
| Krivova, NA | 1 |
| Zaeva, OB | 1 |
| Lesovaya, EA | 1 |
| Kirsanov, KI | 1 |
| Antoshina, EE | 1 |
| Trukhanova, LS | 1 |
| Gorkova, TG | 1 |
| Shipaeva, EV | 1 |
| Salimov, RM | 1 |
| Belitsky, GA | 1 |
| Blagosklonny, MV | 1 |
| Yakubovskaya, MG | 1 |
| Chernova, OB | 1 |
| Savelieva, KV | 1 |
| Kheyfets, IA | 1 |
| Dugina, JL | 1 |
| Sergeeva, SA | 2 |
| Epstein, OI | 1 |
| Borovskaja, TG | 1 |
| Udut, VV | 1 |
| Jurmazov, ZA | 1 |
| Pahomova, AV | 1 |
| Chemerova, JA | 1 |
| Rumpel', OA | 1 |
| Belostotskaya, LI | 1 |
| Gomon, ON | 1 |
| Nikitchenko, YV | 1 |
| Chaika, LA | 1 |
| Bondar, VV | 1 |
| Dzyuba, VN | 1 |
| Van Coppenolle, F | 1 |
| Slomianny, C | 1 |
| Carpentier, F | 1 |
| Le Bourhis, X | 1 |
| Ahidouch, A | 1 |
| Croix, D | 1 |
| Legrand, G | 1 |
| Dewailly, E | 1 |
| Fournier, S | 1 |
| Cousse, H | 1 |
| Authie, D | 1 |
| Raynaud, JP | 1 |
| Beauvillain, JC | 1 |
| Dupouy, JP | 1 |
| Prevarskaya, N | 1 |
| Mongioi, A | 1 |
| Vicari, E | 1 |
| D'Agata, R | 1 |
1 trial available for sulpiride and Prostatic Hyperplasia
| Article | Year |
|---|---|
Modification of sulpiride model of benign prostatic hyperplasia for evaluation of the effectiveness of drug therapy.
Topics: Animals; Antibodies; Disease Models, Animal; Drug Screening Assays, Antitumor; Humans; Male; Middle | 2011 |
10 other studies available for sulpiride and Prostatic Hyperplasia
| Article | Year |
|---|---|
Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia.
Topics: Acinar Cells; Animals; Animals, Outbred Strains; Anti-Inflammatory Agents; Antioxidants; Disease Mod | 2019 |
Morphological Assessment of Prostatotropic Activity of (3,5-Dimethyl-4-Hydroxy)Benzyl Thiododecane on a Model of Benign Prostatic Hyperplasia in Rats.
Topics: Animals; Disease Models, Animal; Down-Regulation; Male; Organ Size; Plant Extracts; Prostate; Prosta | 2019 |
Morphological and Biochemical Characteristics of Prostate Hyperplasia during Sulpiride Treatment.
Topics: Acinar Cells; Animals; Disease Models, Animal; Dopamine Antagonists; Epithelial Cells; Gene Expressi | 2020 |
Comparative evaluation of the efficiency of prostatotropic agents of natural origin in experimental benign prostatic hyperplasia.
Topics: Animals; Cattle; Male; Peptides; Phytotherapy; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats | 2013 |
Dihydroquercetin effects on the morphology and antioxidant/prooxidant balance of the prostate in rats with sulpiride-induced benign hyperplasia.
Topics: Animals; Antioxidants; Histological Techniques; Male; Prostatic Hyperplasia; Quercetin; Rats; Rats, | 2015 |
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.
Topics: Aging; Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Drug Administration Schedule; F | 2015 |
Comparative study of pharmacological activity of afala on the model of hormone-induced prostatitis in rats.
Topics: Animals; Antibodies; Disease Models, Animal; Immunoenzyme Techniques; Male; Organ Size; Plant Extrac | 2007 |
Prooxidant-antioxidant balance in the prostate and blood of rats with sulpyride[corrected]-induced prostatic hyperplasia corrected with prostatilen.
Topics: Animals; Glutathione Peroxidase; Lipid Peroxides; Male; Oxidation-Reduction; Peptides; Prostatic Hyp | 2005 |
Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence.
Topics: Animals; Apoptosis; Chronic Disease; Dihydrotestosterone; Dopamine Antagonists; Gonadal Steroid Horm | 2001 |
The prolactin-secreting system in relation to aging.
Topics: Aged; Aging; Humans; Male; Middle Aged; Prolactin; Prostatic Hyperplasia; Reference Values; Sulpirid | 1985 |